Benjamin Oakes is a prominent inventor based in El Cerrito, CA. He has made significant contributions to the field of biotechnology, particularly in the development of gene repressor systems and nucleic acid editing technologies. With a total of 11 patents to his name, Oakes continues to push the boundaries of innovation in his field.

Latest Patents

Among his latest patents is a groundbreaking invention titled "Compositions and methods for the targeting of PCSK9." This patent describes gene repressor systems that include fusion proteins, such as those comprising a DNA binding domain like a TALE, zinc finger, or catalytically-dead CRISPR protein, along with guide nucleic acid (gRNA). These systems are designed to repress the transcription of the PCSK9 gene, which plays a crucial role in cholesterol regulation. Another notable patent is for "Engineered guide scaffolds," which details engineered Class 2 Type V nucleases and guide RNAs that are useful for editing target nucleic acids. This invention also outlines methods for creating and utilizing these variants to modify nucleic acids effectively.

Career Highlights

Oakes is currently employed at Scribe Therapeutics Inc., where he applies his expertise in gene editing and biotechnology. His work at Scribe Therapeutics has positioned him as a key player in the advancement of therapeutic technologies aimed at addressing various genetic disorders.

Collaborations

Throughout his career, Benjamin Oakes has collaborated with talented individuals such as Sarah Denny and Sean Higgins. These partnerships have fostered an environment of innovation and creativity, leading to the development of cutting-edge technologies in the field.

Conclusion

Benjamin Oakes exemplifies the spirit of innovation in biotechnology through his numerous patents and contributions to gene editing technologies. His work continues to inspire advancements that may significantly impact healthcare and genetic research.